Pharmaceuticals

Global Multiple Sclerosis Treatment Market Overview: Trends Shaping Growth to 2029

November 13, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Multiple Sclerosis Treatment Industry By The Forecast Year 2029?

The multiple sclerosis treatment market has demonstrated robust expansion recently. This market is projected to expand from $24.86 billion in 2024 to $26.13 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.1%. Factors contributing to its historical growth include heightened awareness of initial multiple sclerosis symptoms, improved availability of disease-modifying therapies, an increase in autoimmune disorder prevalence, enhanced neurological healthcare infrastructure, and greater uptake of immunomodulatory treatments.

The multiple sclerosis treatment market size is predicted to show continuous expansion over the next few years. It is forecasted to achieve a value of $31.55 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 4.8%. This expansion in the projected period is driven by various factors, including the increasing approval of innovative monoclonal antibodies, a rising need for personalized multiple sclerosis treatment, an intensified focus on neurodegenerative disease management, the expanding use of telemedicine in multiple sclerosis care, and a growing preference for minimally invasive treatment options. Significant trends anticipated during this forecast period involve technology-based remote monitoring, the creation of remyelination therapies, the development of gut-brain axis treatments, the integration of digital biomarkers, and advancements in digital therapeutics.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24612&type=smp

Which Drivers Are Shaping The Multiple Sclerosis Treatment Industry’s Market Share?

The increasing occurrence of neurological conditions is projected to fuel the expansion of the multiple sclerosis treatment market in the future. These disorders are health issues impacting the brain, spinal cord, and nerves across the body, resulting in difficulties with movement, communication, conduct, or physical functions. An aging global population contributes to the surge in neurological disorders, since extended lifespans elevate the likelihood of age-associated ailments like Alzheimer’s. Treatment for multiple sclerosis aids in addressing neurological disorders through targeting the immune system, thereby lessening inflammation, averting nerve damage, and easing symptoms, which enhances the quality of life for individuals. As an illustration, in October 2023, the World Federation of Neurology, a UK-based association of national neurological societies, reported that over 40% of the world’s population currently suffers from a neurological condition, with this burden anticipated to almost double by 2050. Consequently, the expanding incidence of neurological disorders is stimulating the growth of the multiple sclerosis treatment market.

Which Key Segments Fueling The Multiple Sclerosis Treatment Market?

The multiple sclerosis treatment market covered in this report is segmented –

1) By Treatment Type: Immunomodulators, Corticosteroids, Symptomatic Treatments, Monoclonal Antibodies, Oral Therapies

2) By DiseaseType: Clinically Isolated Syndrome, Relapse-Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis

3) By Route Of Administration: Oral, Injectable, Intravenous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments

1) By Immunomodulators: Interferon Beta-1A, Interferon Beta-1B, Glatiramer Acetate

2) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone

3) By Symptomatic Treatments: Muscle Relaxants, Antidepressants, Anticonvulsants, Bladder Dysfunction Drugs

4) By Monoclonal Antibodies: Natalizumab, Ocrelizumab, Alemtuzumab, Ofatumumab

5) By Oral Therapies: Fingolimod, Dimethyl Fumarate, Teriflunomide, Cladribine, Siponimod

What Key Innovation Trends Are Fueling Advancements In The Multiple Sclerosis Treatment Market?

Leading companies within the multiple sclerosis treatment market are developing advanced products, such as monoclonal antibody drugs, to improve treatment efficacy and patient outcomes. Monoclonal antibody drugs are laboratory-produced molecules designed to target specific antigens; in multiple sclerosis, they function by reducing inflammation and preventing immune cells from attacking nerve fibers, thereby managing the disease’s progression. For example, in February 2024, Roche Pharma India, an India-based pharmaceutical firm, launched Ocrevus (Ocrelizumab) for the treatment of multiple sclerosis (MS). This medication specifically targets CD20-positive B cells, which helps in lessening inflammation and nerve damage in MS. It represents the first approved therapy for both relapsing and primary progressive forms of MS, considerably decreasing relapse rates and slowing the progression of disability with the convenience of twice-yearly infusions.

Which Major Firms Are Strengthening Their Position In The Multiple Sclerosis Treatment Industry?

Major companies operating in the multiple sclerosis treatment market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Biogen Inc., UCB S.A., Mallinckrodt Pharmaceuticals, Acorda Therapeutics Inc., Adamas Pharmaceuticals Inc., Mapi Pharma Ltd., TG Therapeutics Inc., Atara Biotherapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-treatment-global-market-report

Which Region Is Projected To Lead The Multiple Sclerosis Treatment Market During The Forecast Period?

North America was the largest region in the multiple sclerosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple sclerosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Multiple Sclerosis Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24612&type=smp

Browse Through More Reports Similar to the Global Multiple Sclerosis Treatment Market 2025, By The Business Research Company

Rare Neurological Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Neuralgia Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Progressive Multifocal Leukoencephalopathy Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/progressive-multifocal-leukoencephalopathy-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795